

2019 RASsymp Agenda d060619

<i>tentative schedule</i>	<i>description</i>	<i>speaker/moderator</i>
F 8-10pm	Dessert Reception and Poster Session	
8:00-8:15pm	Welcome Remarks	Karen Gripp , MD, Nemours/AI duPont Hospital for Children Nancy Ratner , PhD, Cincinnati Children's Hospital Medical Center Lisa Schoyer , Lisa Schill and Beth Stronach, RASopathies Network
SA 7:00-8:00am	Breakfast	
SA 8:00-8:20am	Introductory Remarks: The RASopathies Umbrella	Katherine A. Rauen , MD, PhD, UC Davis, CA
SA 8:20-10:05am	Session 1: Novel Mutations/Genes in the Field	Moderator: Marco Tartaglia , PhD, Ospedale Pediatrico Bambino Gesù, Rome, Italy
8:20-8:35	LZTR1 - Phenotypic overlap with RASopathies	Martin Zenker , MD, University Hospital of Magdeburg, Germany
8:35-8:50	LZTR1 - Schwannomatosis Phenotype	Anna Sablina ? (Leuven, Belgium)
8:50-9:05	PPP1CB - Molecular Details and Pathway Function	Pablo Rodriguez-Viciana , PhD, University College, London, UK
9:05-9:20	PPP1CB - Phenotypic Overlap with RASopathies	Karen Gripp , MD, Nemours/AI duPont Hospital for Children
9:20-9:35	SYNGAP1 - Molecular Details and Pathway Function	Gavin Rumbaugh , PhD, Scripps Research Institute, FL
9:35-9:50	SYNGAP1 - Phenotypic Overlap with RASopathies	Jimmy Holder , MD, Baylor College of Medicine, TX
9:50-10:05	<i>Discussion over Coffee</i>	
SA 10:05am-11:25am	Session 2: New Functions of RASopathy Genes	Moderator: Emma Burkitt-Wright , MD, PhD, NHS Foundation Trust, Manchester, UK
10:05-10:20	Metabolic Effects in Mouse Model of Costello Syndrome	Shin-ichi Inoue , PhD, Tohoku U School of Medicine, Japan
10:20-10:45	Targeting SHP2 for Neurofibromatosis and Other Malignancies	Ben Neel , PhD, NYU Langone Med Ctr, NY
10:45-11:10	Rit1/LZTR Involvement in RASopathies	Frank McCormick , PhD FRS DSC, UCSF, CA
11:10-11:25	<i>Discussion</i>	
SA 11:25am-12:15pm	KEYNOTE: The inhibitor landscape and Ras signaling feedback loops	Neal Rosen , PhD, MSKCC, NYC
SA 12:20-1:20pm	LUNCH - Presentation: Steph Nimmo, Author "Was This in the Plan?"	
SA 1:30-3:05pm	Session 3: Therapeutic Inhibitors	Moderator: Bill Timmer , NCI (CTEP)
1:30-1:45	Thyroid Cancer Driven by HRAS: Tipifarnib Clinical Trial Results	Alan L. Ho , MD PhD, MSKCC, NYC
1:45-2:00	NCI's Advancing Rasopathies Therapy Project	Andrea Gross , MD, NCI Center for Cancer Research (CCR)
2:00-2:15	Dasatinib for Cardiomyopathy in Noonan Syndrome	Anton Bennett , PhD, Yale, CT
2:15-2:30	Tipifarnib Trials	Catherine Scholz , PharmD, VP Development, Kura Oncology
2:30-2:50	Drugging RAS from Multiple Angles	Darryl McConnell , PhD, Boehringer-Ingelheim, Austria
2:50-3:05	<i>Discussion over Coffee</i>	
SA 3:10-5:15pm	Session 4: Potential Endpoints for Clinical Trials in Rasopathies	Moderator: Nancy Ratner , PhD, Cincinnati Children's Hospital
	The Brain in RASopathies	
3:10-3:25	Mouse Models - Neuronal Dysfunction in Rasopathy Brains	Alcino Silva , PhD, UCLA, CA
3:25-3:40	Antioxidant Testing in Preclinical Models and RASopathy Patients	Carlos Prada , MD, Cincinnati Childrens Hospital
3:40-3:55	Findings in MRI Studies for Cognitive Function: Noonan Syndrome Brains	Tamar Green , PhD, Stanford University, CA
3:55-4:10	Neonates with RASopathies: a Case-Controlled Study	Susan Blaser , MD FRCP, Hospital for Sick Children, Toronto, Canada
	Cardiac Function in RASopathies	
4:10-4:25	Molecular Mechanisms of Cardiovascular Difficulties in RASopathies Patients	Maria Kontaridis , PhD, Masonic Medical Research Lab, Utica, NY
4:25-4:40	Insights from Model Organisms	Rebecca Burdine , PhD, Princeton, NJ
4:40-5:10	<i>Discussion</i>	
SA 6:00-8:00pm	NETWORKING DINNER or CSFN Family Dinner	
SU 7:00-8:00am	Breakfast	
SU 8:00-8:50am	Session 5: Prenatal Findings, Manifestations, Diagnosis and Management	Moderator: Pilar Magoulas , MS CGC, Baylor College of Medicine, TX
8:00-8:40	Panelists:	Sandra Darilek MS CGC, Baylor; Angie Jelin MD- MFM, Johns Hopkins
8:40-8:50	<i>Discussion</i>	
SU 8:50-10:40am	Session 6: Clinical Trial Endpoints Roundtable	Moderator: Richard Klein , former Director of FDA's Patient Liaison Program, WDC Area
8:50-9:05	PPMD: Forefront of PRO	Annie Kennedy , Parent Project Muscular Dystrophy, MD
9:05-9:20	PRO Validations with the FDA	Pam Wolters , PhD, NCI, NIH
9:20-9:35	Cognitive Evaluation of the Effects of Selumetinib in NF1	Karin Walsh , PsyD, Children's Research Inst., WDC [NF1 REINS Consortium]
9:40-10:10	RASopathies Families Voice	Moderated by ? Tuesdi CFC, Greg NF Network, NS, CS
10:10-10:40	<i>Discussion</i>	
SU 10:45am-12:15pm	Session 7: Junior Investigators, MDRB Grantees, Closing Comments	Moderator: Amy Roberts , MD, Harvard Medical School, Boston Children's Hospital
10:45-11:00	Junior Investigator Finalist 1 Presentation	TBD prior to Symposium
11:00-11:15	Junior Investigator Finalist 2 Presentation	TBD prior to Symposium
11:15-11:30	Junior Investigator Finalist 3 Presentation	TBD prior to Symposium
11:30-11:45	Million Dollar Bike Ride 2018 Grantee Presentation	Kartik Venkatachalam , PhD, UT Houston, TX
11:45-12:00	Million Dollar Bike Ride 2019 Grantee Presentation: <i>Advancing a Novel Therape</i>	Bruce Gelb , MD, Mt. Sinai School of Medicine, NY
12:00-12:15	<i>Discussion and Closing Remarks</i>	
SU 12:30-4:00pm	Breakout Sessions	
12:30-1:30pm	Breakout for CFC Families	Pilar Magoulas , MS CGC, Dave Stevenson , MD
12:30-1:30pm	Breakout for CS Families - Hosted by CSFN	Karen Gripp , MD and Emma Burkitt-Wright , MD, PhD
12:30-1:30pm	Breakout for NS, NSML Families	Bruce Gelb , MD and Amy Roberts , MD
TBD	Breakout for NF1 Families - Hosted by NF Network	Bruce Korf MD, PhD
2:30-4:00pm	RASopathies Network Open Meeting	Board members from RASNet and other family support organizations